c-RET
Gli inibitori di c-RET prendono di mira il proto-oncogene RET (Rearranged during Transfection), che codifica una tirosina chinasi recettoriale coinvolta nella crescita, differenziazione e sopravvivenza cellulare. L'attivazione anomala della segnalazione RET può portare a una proliferazione cellulare incontrollata e alla resistenza all'apoptosi, contribuendo allo sviluppo di tumori come il carcinoma midollare della tiroide e il carcinoma polmonare non a piccole cellule. L'inibizione di c-RET può indurre l'apoptosi nelle cellule tumorali ed è un approccio promettente nella terapia oncologica mirata. Presso CymitQuimica, offriamo una varietà di inibitori di c-RET di alta qualità per supportare la tua ricerca in oncologia, trasduzione del segnale e apoptosi.
Trovati 64 prodotti per "c-RET".
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BT-13
CAS:BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.Formula:C23H27F4N3O4SPurezza:99.23%Colore e forma:SolidPeso molecolare:517.54Ref: TM-T10624
1mg40,00€2mg54,00€5mg92,00€1mL*10mM (DMSO)92,00€10mg127,00€25mg208,00€50mg311,00€100mg445,00€RET ligand-3
RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.Formula:C38H42N10O3Colore e forma:SolidPeso molecolare:686.81Compound TPX-0046
CAS:Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.Formula:C21H21FN6O3Purezza:99.94%Colore e forma:SoildPeso molecolare:424.43Cofetuzumab
CAS:Cofetuzumab (PF-06523435) is a antibody targeting protein tyrosine kinase 7 (PTK7), which can be used to synthesize ADC compounds like cofetuzumab pelidotin.Purezza:>95%Colore e forma:LiquidPeso molecolare:146.7 kDaCDD-2807
CDD-2807 is a serine/threonine kinase 33 (STK33) inhibitor with an IC50 of 9.2 nM. In mice, CDD-2807 demonstrates no significant toxicity and can cross the blood-testis barrier without accumulating in the brain. It offers reversible contraceptive effects, indicating potential for development as a male contraceptive.Formula:C29H26N4OPeso molecolare:446.21066RET-IN-29
RET-IN-29 (Compound 8W) is a selective RET kinase inhibitor. It demonstrates inhibitory effects on BaF3 cells with the CCDC6-RETV804M mutation, with an IC50 of 0.715 μM. RET-IN-29 shows potential for research in non-small cell lung cancer (NSCLC).Formula:C22H22N6OColore e forma:SolidPeso molecolare:386.45QZ2135
QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.Formula:C53H54N12O4Colore e forma:SolidPeso molecolare:923.07RET-IN-28
CAS:RET-IN-28 (Compound 16) is an inhibitor of RET (a transmembrane receptor tyrosine kinase). It specifically inhibits the activity of a mutant RET enzyme (RET-V804M) and is utilized in cancer research.Formula:C26H29N9Colore e forma:SolidPeso molecolare:467.57PLM-101
PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.Formula:C22H22FN5O2Colore e forma:SolidPeso molecolare:407.44AD57 (hydrochloride)
CAS:AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.Formula:C22H21ClF3N7OPurezza:98%Colore e forma:SolidPeso molecolare:491.9YW-N-7 TFA
YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.Formula:C58H63F3N12O9Colore e forma:SolidPeso molecolare:1129.19RET Ligand-Linker Conjugate-1
RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.Formula:C40H44N10OColore e forma:SolidPeso molecolare:680.84Zeteletinib hemiadipate
CAS:Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.Formula:C56H56F6N8O12Colore e forma:SolidPeso molecolare:1147.098BT44
CAS:BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.Formula:C28H27F4N3O4SPurezza:99.87%Colore e forma:SolidPeso molecolare:577.59Ref: TM-T67733
1mg71,00€5mg152,00€1mL*10mM (DMSO)178,00€10mg222,00€25mg401,00€50mg602,00€100mg875,00€RET-IN-4
CAS:RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.Formula:C27H31FN10O2Colore e forma:SolidPeso molecolare:546.611ZW-18-116
ZW-18-116 (compound 9) is a dual-target PROTAC degrader focusing on the oncogenic proteins TRKA and RET. It induces the degradation of TRKA and RET by recruiting the CRBN E3 ligase. ZW-18-116 shows potent antiproliferative activity in various cancer cell lines harboring RET or TRKA fusion genes. This compound is applicable to research on RET or TRKA-related cancers such as thyroid, lung, and colon cancers.RET ligand-1
CAS:RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.Formula:C28H24F2N6O3Colore e forma:SolidPeso molecolare:530.525RET-IN-26
RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].Colore e forma:Odour Solidtrans-Pralsetinib
CAS:trans-Pralsetinib (trans-BLU-667) is a RET inhibitor. It targets RET kinase to suppress tumor growth driven by RET mutations or rearrangements; used in lung and thyroid cancer research.Formula:C27H32FN9O2Purezza:98.06%Colore e forma:Transparent ViscousPeso molecolare:533.6TPX-0046
CAS:TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.Formula:C21H21FN6O3Purezza:99.95%Colore e forma:SolidPeso molecolare:424.43Pyrazoloadenine
CAS:Pyrazoloadenine (4-Aminopyrazolo[3,4-d]pyrimidine) is the inhibitor of human xanthine oxidase.Formula:C5H5N5Purezza:99.02%Colore e forma:SolidPeso molecolare:135.13SPP-86
CAS:SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.Formula:C16H15N5Purezza:99.53%Colore e forma:SolidPeso molecolare:277.32Ref: TM-T16923
1mg46,00€5mg90,00€1mL*10mM (DMSO)90,00€10mg144,00€25mg281,00€50mg447,00€100mg650,00€500mg1.369,00€WHI-P180 hydrochloride
CAS:WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.Formula:C16H16ClN3O3Colore e forma:SolidPeso molecolare:333.77Pralsetinib
CAS:Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918TFormula:C27H32FN9O2Purezza:97.88% - 99.8%Colore e forma:White SolidPeso molecolare:533.6WHI-P180
CAS:WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.Formula:C16H15N3O3Purezza:99.21%Colore e forma:White SolidPeso molecolare:297.31AD80
CAS:AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.Formula:C22H19F4N7OPurezza:99.49% - 99.75%Colore e forma:SolidPeso molecolare:473.43Ref: TM-T4301
1mg44,00€1mL*10mM (DMSO)90,00€5mg96,00€10mg138,00€25mg268,00€50mg439,00€100mg645,00€500mg1.333,00€Treprostinil Sodium
CAS:Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).Formula:C23H33NaO5Purezza:99.67% - >99.99%Colore e forma:SolidPeso molecolare:412.5GSK3179106
CAS:GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nMFormula:C22H21F4N3O4Purezza:99.8% - 99.90%Colore e forma:SolidPeso molecolare:467.41Selpercatinib
CAS:"Selpercatinib (LOXO-292) is a RET tyrosine kinase inhibitor with IC50s of 14.0, 24.1, 530.7 nM for different RET mutations."Formula:C29H31N7O3Purezza:99.87% - >99.99%Colore e forma:White SolidPeso molecolare:525.6Ref: TM-T8222
2mg34,00€5mg49,00€1mL*10mM (DMSO)56,00€10mg84,00€25mg166,00€50mg259,00€100mg477,00€200mg692,00€500mg1.035,00€RET V804M-IN-1
CAS:RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).Formula:C19H16N6OPurezza:97.94% - 99.62%Colore e forma:White SolidPeso molecolare:344.37Ref: TM-T8467
1mg35,00€2mg50,00€5mg74,00€1mL*10mM (DMSO)82,00€10mg90,00€25mg157,00€50mg236,00€100mg334,00€200mg495,00€BBT594
CAS:BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.Formula:C28H30F3N7O3Purezza:99.57%Colore e forma:White SolidPeso molecolare:569.58RET-IN-16
CAS:RET-IN-16: Selective RET inhibitor, IC50s 3.98-15.05 nM for various RET mutations; anticancer properties.Formula:C31H29F3N8O2Colore e forma:SolidPeso molecolare:602.61RET-IN-6
CAS:RET-IN-6 is a potent inhibitor of RET (IC50: 4.57 nM).Formula:C30H29N7Colore e forma:SolidPeso molecolare:487.6RET-IN-22
CAS:RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-Formula:C29H31F3N6O4Colore e forma:SolidPeso molecolare:584.59DUN73423
CAS:DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.Formula:C19H16N6OPurezza:98.03%Colore e forma:SolidPeso molecolare:344.37XMD15-44
CAS:XMD15-44, a RET kinase inhibitor, demonstrates potent growth-inhibitory effects on RAT1 cells transformed by RET/C634R and RET/M918T, with IC50 values of 11.5 nM and 8.3 nM, respectively. It effectively inhibits RET kinase activity and signaling in human thyroid cancer cell lines harboring oncogenic RET alleles, thereby reducing cell proliferation.Formula:C29H29F3N4OColore e forma:SolidPeso molecolare:506.56RET-IN-8
CAS:RET-IN-8 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Formula:C27H30N6O3Colore e forma:SolidPeso molecolare:486.57RET-IN-12
CAS:RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).Formula:C30H30F3N5O4Colore e forma:SolidPeso molecolare:581.59RET-IN-15
CAS:RET-IN-15 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.Formula:C27H28N8O2Colore e forma:SolidPeso molecolare:496.56TRK II-IN-1
CAS:TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Formula:C29H31F3N8OPurezza:98%Colore e forma:SolidPeso molecolare:564.6TG-89
CAS:TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian andFormula:C26H34N6O3SPurezza:98.68%Colore e forma:White SolidPeso molecolare:510.65Pz-1
CAS:Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.Formula:C26H26N6O2Purezza:99.89%Colore e forma:White SolidPeso molecolare:454.52RET-IN-23
CAS:RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.Formula:C28H28FN11Purezza:97.46%Colore e forma:SolidPeso molecolare:537.59Ref: TM-T79099
10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta1mg264,00€5mg650,00€RET-IN-3
CAS:RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.Formula:C18H21N5O2Purezza:99.83%Colore e forma:SolidPeso molecolare:339.39RET-IN-17
CAS:RET-IN-17 inhibits RET kinase; may help in IBS pain and RET-activated cancers.Formula:C27H28F4N4O4Colore e forma:SolidPeso molecolare:548.53RET-IN-25
CAS:RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximalFormula:C22H17N3O5SColore e forma:SolidPeso molecolare:435.45FHND5071
CAS:FHND5071, a potent and selective RET kinase inhibitor, exerts antitumor effects through the inhibition of RET autophosphorylation and may be utilized for tumorFormula:C30H30D3N9OColore e forma:SolidPeso molecolare:538.66NSC194598
CAS:NSC194598 is a p53 DNA-binding inhibitor, demonstrating an in vitro IC50 of 180 nM and an in vivo range of 2-40 μM.Formula:C20H19N3OColore e forma:SolidPeso molecolare:317.38FLT3/ITD-IN-4
CAS:FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).Formula:C25H22N4O5Colore e forma:SolidPeso molecolare:458.47RET-IN-24
CAS:RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1].Formula:C27H26F2N8OColore e forma:SolidPeso molecolare:516.55
